Dihydroartemisinin and its derivative induce apoptosis in acute myeloid leukemia through Noxa-mediated pathway requiring iron and endoperoxide moiety

被引:32
作者
Zhao, Xuan [1 ]
Zhong, Hang [2 ]
Wang, Rui [3 ]
Liu, Dan [2 ]
Waxman, Samuel [3 ]
Zhao, Linxiang [2 ]
Jing, Yongkui [3 ]
机构
[1] Shenyang Pharmaceut Univ, Dept Pharmacol, Shenyang, Peoples R China
[2] Shenyang Pharmaceut Univ, Dept Chem Synth, Shenyang, Peoples R China
[3] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Med, New York, NY 10029 USA
基金
美国国家科学基金会;
关键词
Dihydroartemisinin; Noxa; Apoptosis; ABT-737; Acute myeloid leukemia; CHRONIC LYMPHOCYTIC-LEUKEMIA; CELL-DEATH; NEUTROPHIL APOPTOSIS; BH3-ONLY PROTEINS; INTRINSIC PATHWAY; ETHACRYNIC-ACID; HIGH EXPRESSION; DOWN-REGULATION; BH3; MIMETICS; BCL-XL;
D O I
10.18632/oncotarget.3336
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Anti-apoptotic protein Mcl-1 plays an important role in protecting cell from death in acute myeloid leukemia (AML). The apoptosis blocking activity of Mcl-1 is inhibited by BH3-only protein Noxa. We found that dihydroartemisinin (DHA) and its derivative X-11 are potent apoptosis inducers in AML cells and act through a Noxa-mediate pathway; X-11 is four-fold more active than DHA. DHA and X-11-induced apoptosis is associated with induction of Noxa; apoptosis is blocked by silencing Noxa. DHA and X-11 induce Noxa expression by upregulating the transcription factor FOXO3a in a reactive oxygen species-mediated pathway. Interfering with the integrity of the endoperoxide moiety of DHA and X-11, as well as chelating intracellular iron with deferoxamine, diminish apoptosis and Noxa induction. AML cells expressing Bcl-xL, or with overexpression of Bcl-2, have decreased sensitivity to DHA and X-11-induced apoptosis which could be overcome by addition of Bcl-2/Bcl-xL inhibitor ABT-737. DHA and X-11 represent a new group of AML cells-apoptosis inducing compounds which work through Noxa up-regulation utilizing the specific endoperoxide moiety and intracellular iron.
引用
收藏
页码:5582 / 5596
页数:15
相关论文
共 53 条
[1]   The Bcl-2 apoptotic switch in cancer development and therapy [J].
Adams, J. M. ;
Cory, S. .
ONCOGENE, 2007, 26 (09) :1324-1337
[2]   Molecular control of neutrophil apoptosis [J].
Akgul, C ;
Moulding, DA ;
Edwards, SW .
FEBS LETTERS, 2001, 487 (03) :318-322
[3]   Mcl-1 is a potential therapeutic target in multiple types of cancer [J].
Akgul, C. .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2009, 66 (08) :1326-1336
[4]   Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid [J].
Andreeff, M ;
Jiang, S ;
Zhang, X ;
Konopleva, M ;
Estrov, Z ;
Snell, VE ;
Xie, Z ;
Okcu, MF ;
Sanchez-Williams, G ;
Dong, J ;
Estey, EH ;
Champlin, RC ;
Kornblau, SM ;
Reed, JC ;
Zhao, S .
LEUKEMIA, 1999, 13 (11) :1881-1892
[5]   BH3 Mimetics: Status of the Field and New Developments [J].
Billard, Christian .
MOLECULAR CANCER THERAPEUTICS, 2013, 12 (09) :1691-1700
[7]  
Bose Prithviraj, 2013, Leuk Res Rep, V2, P12
[8]   The redox antimalarial dihydroartemisinin targets human metastatic melanoma cells but not primary melanocytes with induction of NOXA-dependent apoptosis [J].
Cabello, Christopher M. ;
Lamore, Sarah D. ;
Bair, Warner B., III ;
Qiao, Shuxi ;
Azimian, Sara ;
Lesson, Jessica L. ;
Wondrak, Georg T. .
INVESTIGATIONAL NEW DRUGS, 2012, 30 (04) :1289-1301
[9]  
Chan HW, 2013, ANTICANCER RES, V33, P4389
[10]   Role of NADPH oxidase in arsenic-induced reactive. oxygen species formation and cytotoxicity in myeloid leukemia cells [J].
Chou, WC ;
Jie, CF ;
Kenedy, AA ;
Jones, RJ ;
Trush, MA ;
Dang, CV .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (13) :4578-4583